Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Rating) major shareholder Morningside Venture Investment sold 29,048 shares of Amylyx Pharmaceuticals stock in a transaction that occurred on Wednesday, March 29th. The stock was sold at an average price of $30.45, for a total value of $884,511.60. Following the completion of the transaction, the insider now directly owns […]
MetLife Investment Management LLC boosted its position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Rating) by 37.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 26,712 shares of the company’s stock after purchasing an additional 7,251 shares during the quarter. MetLife […]
Moody Aldrich Partners LLC acquired a new position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Rating) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 38,064 shares of the company’s stock, valued at approximately $1,406,000. Moody Aldrich Partners LLC owned about 0.06% of Amylyx Pharmaceuticals at […]
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Rating) major shareholder Morningside Venture Investment sold 29,048 shares of the firm’s stock in a transaction that occurred on Wednesday, March 29th. The shares were sold at an average price of $30.45, for a total transaction of $884,511.60. Following the completion of the sale, the insider now owns 6,997,302 […]